The rationale of argon green laser photocoagulation for diabetic maculopathy.
J Postgrad Med
;
1994 Jan-Mar; 40(1): 13-7
Artigo
em Inglês
| IMSEAR
| ID: sea-117026
ABSTRACT
Eighty-four patients of bilateral diabetic retinopathy were divided into 2 groups Group I comprised of 60 patients (mean age 46 yrs) having non-proliferative diabetic retinopathy with maculopathy (total no. of eyes = 120). Group II consisted of 24 patients (mean age 49.1 yrs) with proliferative diabetic retinopathy with maculopathy (total no. of eyes under study = 48). One eye of each patient in group I was treated as a control and the other was subjected to focal laser therapy. While 48/60 control Group I eyes (80%) had 6/24 vision at the outset, at one year follow-up only 39/60 cases (65%) had 6/24 vision. Diabetic maculopathy persisted in all the 60 control eyes at one year. In contrast, 44/60 eyes (73%) subjected to focal laser therapy in Group I, had 6/24 vision at outset but one year later, 49/60 eyes (81%) had 6/24 vision. Maculopathy completely regressed in 48/60 eyes (80%). The 48 eyes of Group II patients were subjected to focal and scatter laser therapy. 20/48 eyes (41.6%) had 6/24 vision prior to treatment but one year after treatment, 25/48 eyes (52%) had 6/24 vision. Neovascularization and macular edema regressed after one year in 42/48 eyes (87.1%) and only 4/48 eyes (8.3%) developed localized vitreous hemorrhage. Laser therapy in Group I improved visual acuity by reducing macular edema. In Group II, it improved the vision and reduced the risk of vitreous hemorrhage, detachment and glaucoma.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Feminino
/
Humanos
/
Masculino
/
Acuidade Visual
/
Neovascularização Retiniana
/
Edema Macular
/
Seguimentos
/
Fotocoagulação a Laser
/
Adulto
/
Retinopatia Diabética
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Idioma:
Inglês
Revista:
J Postgrad Med
Ano de publicação:
1994
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS